Ceapin-A7: Selective Blocker of ER Stress Signaling via ATF6α Pathway Inhibition

Executive Summary: Ceapin-A7 is a small molecule inhibitor that selectively blocks the ATF6α arm of the unfolded protein response (UPR), a critical pathway in endoplasmic reticulum (ER) stress signaling (APExBIO product page). It exhibits an IC₅₀ of 0.59 μM and is chemically defined as C₂₀H₁₂F₆N₄O₃ with a molecular weight of 470.32 g/mol. Ceapin-A7's specificity makes it an essential research tool for dissecting the role of ATF6α in ER stress-associated diseases and cellular stress response studies (Lu Chen et al., 2025). The compound aids in the modeling of protein misfolding disorders and supports advanced translational research through its robust, targeted inhibition profile. Storage, solubility, and handling requirements are standardized to maintain compound integrity for reproducible scientific results.

Biological Rationale

Endoplasmic reticulum (ER) stress arises from the accumulation of misfolded or unfolded proteins within the ER lumen. The cell counters ER stress through the unfolded protein response (UPR), a signaling network comprising the ATF6, IRE1, and PERK pathways (Lu Chen et al., 2025). Hyperactivation of ER stress is implicated in numerous pathologies, including intervertebral disc degeneration (IDD), neurodegenerative diseases, and metabolic syndromes. In the nucleus pulposus cells of intervertebral discs, unresolved ER stress triggers inflammatory cell death (pyroptosis) via interconnected UPR branches. Targeting specific UPR arms, such as ATF6α, allows researchers to untangle disease mechanisms and identify therapeutic targets (Ceapin-A7: Selective Blocker...). Ceapin-A7 provides high selectivity for ATF6α, enabling precise modulation and functional dissection of this UPR component.

Mechanism of Action of Ceapin-A7

Ceapin-A7 acts by selectively inhibiting the ATF6α pathway, a key sensor and effector in the UPR. Under ER stress, ATF6α translocates from the ER to the Golgi, where it is processed to its active form. This active form migrates to the nucleus and induces transcription of ER chaperones and folding enzymes. Ceapin-A7 blocks ATF6α activation at the ER, preventing its Golgi translocation and subsequent nuclear signaling (APExBIO). The inhibition is potent (IC₅₀ = 0.59 μM) and selective, showing minimal off-target activity on other UPR branches (PERK, IRE1). This selectivity is crucial for isolating ATF6α-dependent responses in complex cellular environments (Ceapin-A7: A Selective Blocker...).

Evidence & Benchmarks

• Ceapin-A7 inhibits ATF6α pro-cellular activation with an IC₅₀ of 0.59 μM in cell-based assays (APExBIO).
• Selective ATF6α inhibition by Ceapin-A7 is confirmed by absence of PERK or IRE1 pathway suppression at effective concentrations (Ceapin-A7: A Selective Blocker...).
• In ER stress models, Ceapin-A7 enables functional dissection of ATF6α-dependent gene expression, supporting studies in protein misfolding diseases and inflammation (Ceapin-A7 and the ATF6α Pathway...).
• Recent research highlights the role of UPR signaling (including ATF6) in mediating inflammatory cell death (pyroptosis) in nucleus pulposus cells, underlining the value of highly specific UPR modulators (Lu Chen et al., 2025).
• Ceapin-A7 is soluble in DMSO and stable at -20°C, with degradation observed upon extended solution storage (>24–48 hours at room temperature) (APExBIO).

Applications, Limits & Misconceptions

Ceapin-A7 is widely used as a chemical probe in ER stress research, protein misfolding disease models, and unfolded protein response modulation. Its selectivity for ATF6α allows for targeted mechanistic studies and translational modeling of pathologies involving ER stress.

For a detailed discussion of how Ceapin-A7 empowers translational research into protein misfolding diseases, see this article, which this review extends by providing more recent evidence on ATF6α-specific inhibition. For a comprehensive review of UPR pathway dissection, refer to this resource, which this dossier updates with new citation-backed benchmarks. Finally, a forward-looking strategic perspective is available in this thought-leadership piece, while the current article focuses on validated data and practical workflow parameters.

Common Pitfalls or Misconceptions

• Ceapin-A7 does not inhibit PERK or IRE1 pathways at recommended concentrations; it is strictly an ATF6α inhibitor (APExBIO).
• It is not suitable for diagnostic or therapeutic use in humans or animals; research use only (APExBIO).
• Ceapin-A7 solutions in DMSO are prone to degradation if stored for >48 hours at room temperature (APExBIO).
• ATF6α-independent ER stress responses (e.g., PERK-driven pyroptosis) will not be blocked by Ceapin-A7 (Lu Chen et al., 2025).
• Compound effects must be interpreted in the context of cell-type and ER stressor used; not all stress phenotypes are ATF6α-dependent (Lu Chen et al., 2025).

Workflow Integration & Parameters

• Compound Handling: Ceapin-A7 (SKU: BA3709) is supplied as a solid. Store at -20°C. Reconstitute in DMSO to working concentrations immediately prior to use (APExBIO).
• Solubility: Soluble in DMSO. Avoid aqueous solutions for long-term storage.
• Concentration Range: Effective in cell-based assays at 0.1–1 μM; optimal at 0.59 μM for ATF6α inhibition.
• Controls: Include vehicle (DMSO-only) and stressor-only controls in all experiments.
• Shipping: Ships on blue ice to preserve molecular integrity during transit.
• Safety: For research use only; not for diagnostic or therapeutic applications.

Conclusion & Outlook

Ceapin-A7, offered by APExBIO, is a benchmark tool for selective inhibition of the ATF6α branch of the unfolded protein response. Its potency and specificity enable advanced ER stress research, modeling of protein misfolding diseases, and mechanistic studies of cellular stress responses. Recent evidence underscores the need to precisely target UPR pathways, as different arms (PERK, ATF6, IRE1) have distinct and sometimes synergistic roles in cell fate and inflammation (Lu Chen et al., 2025). Ceapin-A7's validated profile supports its continued application in dissecting the molecular underpinnings of ER stress-linked pathologies and in guiding therapeutic target discovery. For further product details and ordering, visit the Ceapin-A7 product page.